ライフサイエンスコーパス: menstrual

1 function (evaluated by yearly assessment of menstrual activity and defined as resumed by the occurre

2 , vincristine, procarbazine, and prednisone, menstrual activity was strongly related to age (< v >/=

3 nt development of BPD or PH at 36 weeks post-menstrual age (PMA) is unknown.

4 Fifty-seven subjects (31-49 weeks' post-menstrual age) who had an SD-OCT scan in at least 1 eye

5 ssible markers of estrogen exposure, various menstrual and reproductive features, e.g., ages at menar

6 sms, family history, anthropometric factors, menstrual and/or reproductive factors, and lifestyle fac

7 mily history, height, and some components of menstrual and/or reproductive history) and modifiable fa

8 Anticoagulant-associated heavy menstrual bleeding (HMB) is an underrecognized but not u

9 investigate common pathologies such as heavy menstrual bleeding (HMB).

10 I: 0.72, 1.05) comparing <3 with 3-4 days of menstrual bleeding and 0.70 (95% CI: 0.43, 1.13) compari

11 bleeding events, including 59 cases of heavy menstrual bleeding and 13 bleeding events unrelated to t

12 A 47-year-old black woman has heavy menstrual bleeding and iron-deficiency anemia.She report

13 considered a first-line treatment for heavy menstrual bleeding and should be considered, especially

14 potential effect of anticoagulant therapy on menstrual bleeding at the time of treatment initiation.

15 51 (86%) of these heavy menstrual bleeding events (two major bleeding events, 17

16 ect oral factor Xa inhibitors might increase menstrual bleeding intensity in women of reproductive ag

17 al treatment in reducing the effect of heavy menstrual bleeding on quality of life.

18 tween groups, the risk of 2 or more abnormal menstrual bleeding patterns after injury was significant

19 Menstrual bleeding patterns are considered relevant indi

20 ters for each woman that summarize change in menstrual bleeding patterns during the menopausal transi

21 Changes in women's menstrual bleeding patterns precede the onset of menopau

22 or progestin hormonal therapy to control the menstrual bleeding without increased risk for recurrent

23 ghout the cycle were associated with heavier menstrual bleeding, and higher follicle-stimulating horm

24 Vaginal bleeding, particularly heavy menstrual bleeding, is a common complication in women of

25 lood, semen, saliva, vaginal secretions, and menstrual blood--in an attempt to identify putative body

26 The authors examined the association between menstrual characteristics and time to pregnancy among 2,

27 thors identify population subgroups based on menstrual characteristics of the menopausal transition e

28 Menstrual characteristics were reported at baseline.

29 Complete menstrual collections were obtained from 13 women.

30 inflammation in patients with arthritis and menstrual cramps, but they have not provided any benefit

31 and young women, is characterized by painful menstrual cramps.

32 s in the follicular and luteal phases of the menstrual cycle (FDR-adjusted p-value <0.05).

33 hat was tailored to metabolic changes of the menstrual cycle (Menstralean) or to undergo simple energ

34 men were scanned at 2 discrete phases of the menstrual cycle (midcycle and late luteal).

35 Menstrual cycle activity is the most important risk fact

36 erm contraceptive in the luteal phase of the menstrual cycle also had a 3.25 times higher frequency o

37 hypothesis that hormonal fluctuations of the menstrual cycle alter sympathetic neural activity and or

38 of 8 women studied during two phases of the menstrual cycle and 3 women studied during their midfoll

39 Hormonal changes across the menstrual cycle and during the postpartum and perimenopa

40 y symptoms with hormonal changes through the menstrual cycle and imply a potential for individualized

41 Phase of the current menstrual cycle and OC use were significant determinants

42 a diversity and inflammation (controlled for menstrual cycle and other confounders).

43 ion of hormonal signalling as a phenocopy of menstrual cycle and pregnancy-like endocrine loops and h

44 ory symptoms varied significantly during the menstrual cycle and were most frequent from the midlutea

45 ics and hormonal changes associated with the menstrual cycle are possible explanations for variable i

46 performance in such environments across the menstrual cycle are sparse, with mixed findings.

47 lls from women in the ovulatory phase of the menstrual cycle but not from men and identify a function

48 e HPV prevalence preceded the beginning of a menstrual cycle by 9-12 days.

49 om the follicular to the luteal phase of the menstrual cycle by blocking the conversion of progestero

50 DTI parameters are not sensitive to menstrual cycle changes, while menopause, long-term HRT,

51 ed to target and moderate the effects of the menstrual cycle compared with the effect of simple energ

52 ype evident in vivo during the course of the menstrual cycle corresponding to fluctuating estradiol l

53 We assessed endometrial thickness for each menstrual cycle day (as an index of hormone regulation)

54 dings of the present study indicate that the menstrual cycle does not affect muscle sympathetic nerve

55 These results suggest that the menstrual cycle does not affect sympathetic neural activ

56 based therapies and should be tracked in the menstrual cycle during the course of PTSD treatment.

57 r (PMDD) when given daily or for half of the menstrual cycle during the luteal phase.

58 ption, reproductive hormones, and markers of menstrual cycle dysfunction including sporadic anovulati

59 iated with reduced testosterone and improved menstrual cycle function in healthy premenopausal women.

60 e associations between caffeine exposure and menstrual cycle function, and we are aware of no previou

61 appear to have adverse short-term effects on menstrual cycle function, including sporadic anovulation

62 ssess RR of cycle-average alcohol intake and menstrual cycle function.

63 own between cycle-average alcohol intake and menstrual cycle function.

64 en during increasing BP (i.e. phase IV); the menstrual cycle had no influences on cardiovagal baroref

65 human papillomavirus (HPV) DNA detection and menstrual cycle has been inconsistent.

66 DSM-IV and timing of their expression in the menstrual cycle have had little empirical support.

67 varian follicles to produce the human 28-day menstrual cycle hormone profile, which controls human fe

68 e scanned twice based on normal variation in menstrual cycle hormones [i.e., early follicular (EF) co

69 ariations in respiratory symptoms during the menstrual cycle in a general population, and potential m

70 s, we hypothesized that BRCA1 influences the menstrual cycle in a way that mimics the factors underly

71 nd lesions vary according to the week of the menstrual cycle in benign but not in malignant lesions.

72 HSV entry receptor expression throughout the menstrual cycle in genital tissues was performed, and th

73 als, SHIV infections occurred earlier in the menstrual cycle in STI-positive macaques (P = .01, by th

74 progesterone titres during these days of the menstrual cycle in the same groups.

75 tivity did not vary significantly by week in menstrual cycle in women who had undergone mammography m

76 underlying blood pressure control across the menstrual cycle in women with POTS are unknown.

77 mptoms of orthostatic intolerance across the menstrual cycle in women with POTS.

78 mptoms of orthostatic intolerance across the menstrual cycle in women with POTS.

79 Hormonal fluctuations during the menstrual cycle influence energy intake and expenditure

80 5% confidence interval (CI): 0.87, 0.97) and menstrual cycle length (for >/=30 days vs. <30 days, OR

81 [4.00] years and 13 women with no change in menstrual cycle length with a mean [SD] age of 44.92 [2.

82 41] years; including 14 women with change in menstrual cycle length with a mean [SD] age of 45.50 [4.

83 for perimenopause, which is mainly based on menstrual cycle length, was not associated with MAO-A VT

84 tion as against single ovulation in a normal menstrual cycle makes the procedure dependent on several

85 ravings and metabolic changes throughout the menstrual cycle may increase weight loss above that achi

86 onadal hormones, especially estrogen, in the menstrual cycle may play a critical role in fear extinct

87 teroid levels during the luteal phase of the menstrual cycle may precipitate affective symptoms.

88 omen, one in two of such women believe their menstrual cycle negatively impacts training and performa

89 eveloped to model hormonal regulation of the menstrual cycle of a woman from age 20 to 51.

90 estrus but not in the diestrus stage of the menstrual cycle of females was inhibited by pioglitazone

91 After one menstrual cycle of single-blind placebo, participants we

92 he impact of hormonal fluctuation during the menstrual cycle on the course of bipolar disorder is poo

93 age 18-50 years; 115 male and 45 female) and menstrual cycle phase (29 follicular and 16 luteal) effe

94 on of sleep and waking while controlling for menstrual cycle phase and hormonal contraceptive use.

95 e group, prospective, observational trial of menstrual cycle phase and outcome after breast cancer su

96 Menstrual cycle phase does not appear to affect exercise

97 ed for standardization of CRP measurement to menstrual cycle phase in reproductive-aged women.

98 cal confirmation of overnight abstinence and menstrual cycle phase, analyses were performed to compar

99 with genital antiretroviral concentrations, menstrual cycle phase, bacterial vaginosis, genital blee

100 se in well-trained women are not affected by menstrual cycle phase, but differ between dry and humid

101 response circuitry were dependent on women's menstrual cycle phase.

102 essions occurring during hormonally distinct menstrual cycle phases.

103 ar menstrual cycle, undergoing treatment for menstrual cycle regularity shortly after menarche, havin

104 Menstrual cycle status was based on the last menstrual p

105 rointestinal system, adjusts itself with the menstrual cycle to control the passage of sperm, and shi

106 Normal menstrual cycle variations in cortical excitability are

107 he mutations adjusted for age and day of the menstrual cycle was higher (odds ratio [OR] 1.11, 95% CI

108 Regular menstrual cycle was reported by more than 90% of female

109 Significant rhythmic variations over the menstrual cycle were found in each symptom for all subje

110 in premenopausal women according to week of menstrual cycle were studied by using prospectively coll

111 Genital secretions and tissues during the menstrual cycle were studied.

112 r, periovulatory, and luteal phases of their menstrual cycle were studied.

113 were stratified according to the week of the menstrual cycle when MR imaging was performed.

114 of the estrus cycle (equivalent to the human menstrual cycle) and of circulating levels of estradiol

115 d as resumed by the occurrence of at least 1 menstrual cycle), pregnancies, and disease-free survival

116 bility (probability of conception in a given menstrual cycle).

117 between diets (and low hormone phase of the menstrual cycle).

118 Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-i

119 mammography performance according to week of menstrual cycle, adjusting for age and registry.

120 nguished by age at onset, variability of the menstrual cycle, and duration of the early transition.

121 were detected during the luteal phase of the menstrual cycle, and longitudinal analysis showed the fr

122 because these hormones fluctuate across the menstrual cycle, and these fluctuations can complicate c

123 n the periovulatory and luteal phases of the menstrual cycle, and to assess the role of androgens.

124 atients up to 53 y old, predominantly at mid menstrual cycle, and were best coregistered to the fallo

125 men included in this review are pain and the menstrual cycle, contraception, and preconception counse

126 en concentrations fluctuate over the estrous/menstrual cycle, dynamically modulating estrogen recepto

127 resses genital virus shedding throughout the menstrual cycle, even in the presence of factors reporte

128 ncy virus (SHIV) susceptibilities during the menstrual cycle, likely caused by cyclic variations in i

129 e not significantly affected by phase of the menstrual cycle, oral contraceptive use, or early pregna

130 men in the low oestrogen (E(2)) phase of the menstrual cycle, PE evoked a decrease in cRCF (30-40%; P

131 Hormone parameters, menstrual cycle, symptoms of hypogonadism, and offspring

132 between thyroid cancer and having irregular menstrual cycle, undergoing treatment for menstrual cycl

133 he endogenous fluctuation in E(2) during the menstrual cycle, we conducted a within-person repeated-m

134 This could be the case during the menstrual cycle, when using hormone-based birth control,

135 breast DTI is not restricted throughout the menstrual cycle, whereas the modulations in diffusion pa

136 eatability, remaining almost equal along the menstrual cycle, with a low mean within-subject coeffici

137 V/SHIV has been recently associated with the menstrual cycle, with particular susceptibility observed

138 s relatively stable during this stage of the menstrual cycle, with small-scale changes affecting 5% o

139 cise performance is not different across the menstrual cycle, yet is lower in humid heat, in conjunct

140 The menstrual cycle-dependent expression of melanoma antigen

141 anscranial magnetic stimulation to determine menstrual cycle-related changes in cortical excitability

142 Menstrual cycle-specific estimates of urinary BPA and ph

143 endometrial methylome changes throughout the menstrual cycle.

144 he progesterone-dominant luteal phase of the menstrual cycle.

145 tenuated by hormonal fluctuations within the menstrual cycle.

146 cular (EF) and mid-luteal (ML) phases of the menstrual cycle.

147 ions in orthostatic tolerance throughout the menstrual cycle.

148 erwent imaging weekly, four times during one menstrual cycle.

149 enital than plasma concentrations across the menstrual cycle.

150 to oocytes or matured follicles in a single menstrual cycle.

151 e expressed in all tissues during the entire menstrual cycle.

152 trols, matched with respect to age, sex, and menstrual cycle.

153 yclicity of cortical excitability across the menstrual cycle.

154 n the kinetic parameters and the week of the menstrual cycle.

155 follicular and (2) mid luteal phases of the menstrual cycle.

156 ercising in dry and humid heat, across their menstrual cycle.

157 trually in women along with the variation in menstrual cycle.

158 s shed and regenerated each month during the menstrual cycle.

159 ibution for the chance of conceiving in each menstrual cycle.

160 in the high, but not low E(2), phase of the menstrual cycle.

161 women in the low or high E(2) phases of the menstrual cycle.

162 be encountered in vivo throughout the female menstrual cycle.

163 from women with endometriosis throughout the menstrual cycle.

164 ing mammography during the 1st week of their menstrual cycle.

165 predominantly in premenopausal women at mid menstrual cycle.

166 formance did not differ according to week of menstrual cycle.

167 impaired in women and can be affected by the menstrual cycle.

168 ferent between sexes but not affected by the menstrual cycle.

169 ive hormones important for regulation of the menstrual cycle.

170 attern, in which seizures fluctuate with the menstrual cycle.

171 ular (EFP) and mid-luteal phase (MLP) of the menstrual cycle.

172 tissue going through remarkable changes each menstrual cycle.

173 pre-receptive and receptive phase within one menstrual cycle.

174 ing the follicular and luteal phases of each menstrual cycle.

175 from three specimens spaced throughout each menstrual cycle.

176 ding and 13 bleeding events unrelated to the menstrual cycle.

177 Food intake fluctuates throughout the menstrual cycle; it is greater during the early follicul

178 from Western New York were followed for </=2 menstrual cycles (2005-2007) and provided fasting blood

179 tate were followed prospectively for up to 2 menstrual cycles (n = 259) during 2005-2007.

180 York were followed prospectively for up to 2 menstrual cycles (n = 259).

181 trial cancer, we created the total number of menstrual cycles (TNMC) that a woman experienced during

182 st-morning urine specimens during one to two menstrual cycles and male partners collected specimens d

183 gh it is well established that the number of menstrual cycles and pregnancy (in this case transiently

184 articipants (n = 259) were followed for </=2 menstrual cycles and provided fasting blood specimens </

185 the markers are measures based on successive menstrual cycles and the subsequent event is the final m

186 No or irregular maternal menstrual cycles before pregnancy were associated with h

187 s (mean age 24.3 +/- 4.9 years) with regular menstrual cycles between 23 and 35 days.

188 (EBT) (n = 13) had a lower body mass, fewer menstrual cycles in the past year, lower estradiol and 2

189 ture chances of pregnancy from the number of menstrual cycles over which they have been trying to con

190 Six healthy women with regular menstrual cycles were administered the NKB antagonist AZ

191 Women with regular menstrual cycles who presented to a participating family

192 cesses, such as cell cycle, circadian clock, menstrual cycles, are governed by oscillatory systems co

193 were randomized to receive, for the next two menstrual cycles, either double-blind placebo or dutaste

194 y premenopausal women were followed for </=2 menstrual cycles, with biomarkers of lipid peroxidation

195 ued until the first few days of menses for 6 menstrual cycles.

196 western New York State, were followed for 2 menstrual cycles.

197 ar, ovulatory and mid-luteal phases of their menstrual cycles.

198 s simplex virus type 2 coinfection, during 2 menstrual cycles.

199 from the western New York region for up to 2 menstrual cycles.

200 ound in a cohort of 422 controls with normal menstrual cycles.

201 y women aged 18-44 y were followed for </= 2 menstrual cycles.

202 lowed 259 healthy women for up to 2 complete menstrual cycles.

203 ere between 18 and 40 years old with regular menstrual cycles.

204 est and reference tampons in two consecutive menstrual cycles.

205 A total of 221 participants contributed 706 menstrual cycles.

206 matase inhibitors on the dynamics of women's menstrual cycles.

207 olled, cross-over trials, each lasting three menstrual cycles.

208 d with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatme

209 the BioCycle Study were followed for up to 2 menstrual cycles; they provided fasting blood specimens

210 reased by about 2.5% for every additional 10 menstrual-cycles.

211 2 expression, which persisted independent of menstrual cycling.

212 s population and reliance on self-report for menstrual disturbances and LEA.

213 rplay between low energy availability (LEA), menstrual disturbances, and decreased bone mineral densi

214 e to sexual side effects (e.g., infertility, menstrual disturbances, and impotence).

215 mouse model of endometriosis using syngeneic menstrual endometrial tissue introduced into the periton

216 regularization, and duration or intensity of menstrual flow were not appreciably associated with fecu

217 intrauterine system, tranexamic acid (during menstrual flow), high-dose progestin-only therapy, or co

218 ns, including young healthy women with heavy menstrual flow.

219 l pain during menstruation along with normal menstrual flow.

220 s ranging from primary amenorrhea to loss of menstrual function prior to age 40.

221 Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies

222 Menstrual history and hormone levels were used to determ

223 he findings were correlated with the age and menstrual history of the patient.

224 The objective was to evaluate diet, menstrual history, serum hormone concentrations, and bon

225 Differing approaches to menstrual hygiene management (MHM) have been associated

226 tus, number of live births, age at menarche, menstrual irregularity, age at first birth, stillbirths,

227 , gonadal failure, erectile dysfunction, and menstrual issues in SCD.

228 gy, and dopamine has also been implicated in menstrual migraine.

229 nges, which might lead to the development of menstrual migraine.

230 ve important health implications, monitoring menstrual patterns after concussion may be warranted in

231 may have increased risk of multiple abnormal menstrual patterns after concussion.

232 Brain injury may interrupt menstrual patterns by altering hypothalamic-pituitary-ov

233 Because abnormal menstrual patterns can have important health implication

234 n, 16 (23.5%) experienced 2 or more abnormal menstrual patterns during the study period compared with

235 messages received by patients, yielding 487 menstrual patterns in 128 patients (mean [SD] age, 16.2

236 To compare abnormal menstrual patterns in adolescent and young women after a

237 evaluate the association of concussion with menstrual patterns in young women.

238 en use estimates from this model to classify menstrual patterns into subgroups using a K-medoids algo

239 luteinizing hormone and added information on menstrual patterns to determine menopausal status using

240 Menstrual patterns were assessed using a weekly text mes

241 Abnormal menstrual patterns were defined by an intermenstrual int

242 Early age at the natural final menstrual period (FMP) or menopause has been associated

243 ctors are greater within a year of the final menstrual period (FMP), relative to changes that occur b

244 m 10 years before to 8 years after the final menstrual period (FMP), with a decrease of approximately

245 nsisting of measures found on the 1989 (last menstrual period (LMP) and clinical estimate) and 2003 (

246 prenatal care, a nonmissing date of the last menstrual period (LMP), and early ultrasound (n = 1,135)

247 tarted 3-drug ART regimens before their last menstrual period and did not switch or stop ART in pregn

248 cipants who had reliable information on last menstrual period and gestational age confirmed by crown-

249 n in which seizures are clustered around the menstrual period associated with neurosteroid withdrawal

250 gnancy, defined as the first day of the last menstrual period before conception.

251 eing severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not

252 l age more accurately than it predicted last menstrual period gestational age.

253 rongly associated with methylation than last menstrual period gestational age.

254 Her last menstrual period occurred 2 weeks prior to presentation.

255 s in CVD risk factors before and after final menstrual period or surgery.

256 ing the period from 3 months before the last menstrual period through 1 month after delivery and thei

257 in Medicaid from 3 months before their last menstrual period through at least 1 month after delivery

258 Having a higher income and regular menstrual period were negatively associated with lower u

259 y pregnancy loss (within 6 weeks of the last menstrual period) among women attempting pregnancy.

260 from 4 weeks prior to 8 weeks after the last menstrual period).

261 icular or luteal phase using days since last menstrual period, and analyzed by tandem mass spectromet

262 ly healthy, within three years of their last menstrual period, and free of current or past CV disease

263 demographic characteristics, season of last menstrual period, apparent temperature, air basin of mot

264 iving in the same residence since their last menstrual period, in households served by a private wate

265 profuse bone loss begins 3 y before the last menstrual period, when serum estrogen is relatively norm

266 tionally used to compare ultrasound and last menstrual period-based gestational age predictions.

267 Menstrual cycle status was based on the last menstrual period.

268 cycles and the subsequent event is the final menstrual period.

269 computed using both ultrasound and the last menstrual period.

270 s were 52.6 y old, and 1.4 y past their last menstrual period.

271 ressful events, strenuous physical activity, menstrual periods, and high-fat food consumption prior t

272 s (n = 87; ages 18-40 years) during both the menstrual phase (MP; cycle day 1-2; low E+), and the fol

273 trations were significantly increased during menstrual phase and 24 h post-progesterone-withdrawal re

274 ic and autonomic differences associated with menstrual phase and dry vs. humid heat.

275 forearm blood flow differed as a function of menstrual phase and environment (interaction: P </= 0.01

276 ll-trained women exercising in the heat: (1) menstrual phase did not affect performance, (2) humidity

277 A growing literature indicates sex and menstrual phase differences in responses to nicotine.

278 The aim of this study was to assess sex and menstrual phase influences on a broad range of measures

279 Data were unaffected by menstrual phase.

280 cted from 18,521 women during the mid-luteal menstrual phase.

281 neither DFS nor OS differed with respect to menstrual phase.

282 8 to 35 y, were seen during their follicular menstrual phase.

283 ry and hormone levels were used to determine menstrual phase: luteal, follicular, and other.

284 Mean skin temperature did not differ between menstrual phases (P >/= 0.13) but was higher in DRY than

285 lex sensitivity is similar between sexes and menstrual phases during a hypotensive stimulus.

286 uring tilting were similar between sexes and menstrual phases, increases in total activity were lower

287 in human endometrium from late secretory and menstrual phases.

288 mpared with late follicular-midcycle (LF/MC) menstrual phases].

289 ate mechanisms responsible for regulation of menstrual physiology and to investigate common pathologi

290 Age at menarche, time to menstrual regularization, and duration or intensity of m

291 Mothers who took a menstrual regulation supplement were more likely than mo

292 ithout cleft palate (CL +/- P) risk and that menstrual regulation supplements would increase CL +/- P

293 model of menstruation, validating its use in menstrual research.

294 The 5-year cumulative incidence estimate of menstrual resumption was 72.6% (95% CI, 65.7%-80.3%) amo

295 P axis in endometriosis patients compared to menstrual stage matched healthy fertile controls in hope

296 The quantitative BEC was associated with the menstrual status (BEC in premenopausal women, 31.48 +/-

297 FSH and inhibin B levels correlated with menstrual status.

298 2,463 age-matched comparison women with few menstrual symptoms.

299 n several, androgen excess and cutaneous and menstrual symptoms.

300 olated from pulmonary post-influenza TSS and menstrual vaginal TSS, respectively, were evaluated.